Responsible AI in Clinical Trials Summit – Navigating New Regulatory Guidance and Industry Expertise

As the European Medicines Agency (EMA) releases its latest guidance on the safe use of large language models (LLMs) in regulatory science, Cyntegrity is excited to announce the Responsible AI in Clinical Trials Summit. Taking place on October 8-9, 2024, this free virtual event will address the growing importance of AI in clinical trials, exploring how organizations can adopt AI responsibly and ensure safety, trust, and reliability.

The summit will feature key speakers from across industries, with a focus on sharing practical knowledge that can be applied to clinical research. With the EMA highlighting the need for proper governance, privacy, and accuracy in AI implementations, this summit comes at the perfect time to help BioPharma professionals navigate these emerging challenges.

Quotes from Leadership:

"We’re on the verge of a new era in clinical trials, where AI processes data and understands human emotions and preferences," said Artem Andrianov, PhD, CEO & Founder of Cyntegrity. "The summit is designed to show how we can leverage AI’s power to create a future where technology and humanity collaborate to improve healthcare outcomes."

Cyntegrity’s Chief Marketing Officer, Linda Bunschoten, added: "For years, AI has been at the heart of Cyntegrity’s work. Now, as AI becomes accessible to users at every level, questions about trust and control are more pressing than ever. We’re eager to hear from Dr. Mary Jo Lamberti of Tufts CSDD, who will share her latest findings on AI use in clinical research."

Keynote and Speaker Highlights:

  • Simon Krastetter and Yorrick von Ohlen from EY Risk Consulting will present a keynote on “Navigating AI Legislation." They will focus on the latest regulations and what they mean for AI in clinical trials.
  • Wole Moses, Chief AI Officer at Microsoft Federal Civilian, and Danny Goh, co-author of the bestseller "The AI Republic," will bring their expertise to the summit. Both will offer their views on how AI is reshaping our daily work and how industries can build confidence in these technologies.
  • Dr. Mary Jo Lamberti from Tufts CSDD will reveal new data on the uptake of AI in clinical trials with her presentation, “Tufts CSDD Reports on the Uptake of AI in Clinical Research: Trial Planning & Execution.”


Why Attend:

This summit offers a valuable opportunity for anyone involved in clinical research to learn about the latest regulatory developments and practical applications of AI. With insights from leaders across different industries—including BioPharma, AI, and risk consulting—attendees will leave with actionable knowledge to improve their clinical trials.

For more information and to register, visit: Responsible AI in Clinical Trials Summit

Join us to explore how AI is changing the future of clinical research!

Über die Cyntegrity Germany GmbH

Cyntegrity is a global leader in risk-based quality management for clinical trials, helping organizations adopt innovative technologies like AI to improve outcomes and ensure compliance. With a deep commitment to ethical AI use, Cyntegrity empowers BioPharma professionals to advance their clinical research efforts.

Firmenkontakt und Herausgeber der Meldung:

Cyntegrity Germany GmbH
Altenhöferallee 3
60438 Frankfurt am Main
Telefon: +49 (0) 6192-470-113-50
https://cyntegrity.com/

Ansprechpartner:
Marketing department of Cyntegrity
Telefon: +49 (0) 619247011350
E-Mail: marketing@cyntegrity.com
Für die oben stehende Story ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel